Evidence map›Paper›PMID 39836056›Full record

Observational studyJournal of comparative effectiveness research2025

MOMENT registry: Patients with advanced non-small-cell lung cancer harboring

Michael Thomas, Petros Christopoulos, Wade T Iams, Julien Mazières, Alexis B Cortot, Nir Peled, Gabriele Minuti, Egbert F Smit, Francois Audhuy, Karin Berghoff and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Michael ThomasDepartment of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital & National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ & Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Petros ChristopoulosDepartment of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital & National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ & Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Wade T IamsDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Julien MazièresCHU de Toulouse, Université Paul Sabatier, Toulouse, France.
Alexis B CortotUniversité de Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 - UMR-S 1277 - Canther, F-59000 Lille, France.
Nir PeledHelmsely Cancer Center, Shaare Zedek Medical Center, Jerusalem, Israel.
Gabriele MinutiClinical Trial Center: Phase 1 & Precision Medicine, IRCCS, Regina Elena National Cancer Institute, 00144, Rome, Italy.
Egbert F SmitDepartment of Pulmonary Diseases, Leiden University Medical Centre, Leiden, The Netherlands.
Francois AudhuyMerck Serono S.A.S., Lyon, France, an affiliate of Merck KGaA.
Karin BerghoffGlobal Patient Safety, Merck Healthcare KGaA, Darmstadt, Germany.
S Peter EggletonGlobal Clinical Development, Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA.
Frank FriesData Monitoring Management & Innovation, Merck Healthcare KGaA, Darmstadt, Germany.
Maike HildenbrandCompanion Diagnostics & Biomarker Strategy, Merck Healthcare KGaA, Darmstadt, Germany.
Peter LiuGlobal Development Operations, Merck Serono Pharmaceutical R&D Co., Ltd., Beijing, China, an affiliate of Merck KGaA.
Seyed Hamidreza MahmoudpourDepartment of Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.
Christoph MenzelCompanion Diagnostics & Biomarker Strategy, Merck Healthcare KGaA, Darmstadt, Germany.
Dina OksenDepartment of Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-metRegistriesExonsFemaleHumansMaleMiddle AgedProspective StudiesAntineoplastic AgentsMET protein, humanProto-Oncogene Proteins c-metcancer registryMETex14 skippingNSCLCreal-world datatargeted therapy

Identifiers

PMID39836056
PMCPMC11773919

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.